Milurit (Allopurinol)

Allopurinol is a hypoxanthine analogue that competitively inhibits xanthine oxidase, the enzyme responsible for converting hypoxanthine to xanthine and xanthine to uric acid. This inhibition decreases uric acid production, leading to lower blood uric‑acid concentrations.

The dosage of Milurit is individualized by the prescribing clinician based on the patient’s uric‑acid level, renal function, and therapeutic goal. Typical adult regimens start with a low dose and are titrated upward, but the exact amount and schedule must be determined by a qualified health professional.

Safety data for allopurinol in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by the treating physician in consultation with the patient.

To place an order, submit an enquiry on the Milurit product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Milurit (allopurinol) is a first‑line xanthine oxidase inhibitor, whereas alternatives such as febuxostat belong to the same class but have different metabolic pathways and dosing considerations. Allopurinol is generally less expensive and has a long safety record, but individual response and tolerability guide the choice of therapy.

Milurit should be stored at temperatures below 25 °C, in its original container, protected from moisture and direct sunlight. Keep the product out of reach of children and do not use it after the expiry date printed on the packaging.

Milurit is taken orally, usually with a full glass of water. It can be taken with or without food, but consistent timing each day helps maintain stable blood levels. Patients should follow the prescribing clinician’s instructions regarding dose timing and any necessary dose adjustments.

The most serious adverse reactions include severe hypersensitivity syndromes such as Stevens‑Johnson syndrome, toxic epidermal necrolysis, and drug‑induced agranulocytosis or hepatic failure. Prompt medical attention is required if signs of rash, fever, jaundice, or unexplained fatigue develop while taking Milurit.

Milurit is contraindicated in patients with a known hypersensitivity to allopurinol or any component of the formulation. Caution is also advised for individuals with severe renal impairment, active liver disease, or those taking interacting medications such as azathioprine, unless a clinician determines the benefits outweigh the risks.